ArticleACS omega2018
Therapeutic Radiopharmaceuticals Targeting Integrin αvβ6.
Article in ACS omega, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Article
- Linker Optimization in Lu-177 Labeled αvβ6-Integrin Binding Peptide Trimers for Targeted Radionuclide Therapy of Cancer.Molecular pharmaceutics · 2026Article
- Peptide-Guided Photodynamic Therapy via Integrin αvβ6 in Pancreatic Cancer.International journal of molecular sciences · 2026Article
- Article
- The importance of tyrosines in multimers of cyclic RGD nonapeptides: towards αvβ6-integrin targeted radiotherapeutics.RSC medicinal chemistry · 2024Article
- Complexity of αvβ6-integrin targeting RGD peptide trimers: emergence of non-specific binding by synergistic interaction.RSC medicinal chemistry · 2023Article
- Pilot-phase PET/CT study targeting integrin αEuropean journal of nuclear medicine and molecular imaging · 2022Article
- A Comparison of Evans Blue and 4-(Pharmaceutics · 2022Article
- PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the "Cancer Integrin" αvβ6 with Ga-68-Trivehexin.European journal of nuclear medicine and molecular imaging · 2022Article
- Therapeutic Efficacy ofPharmaceuticals (Basel, Switzerland) · 2022Article
- It's Time to Shift the Paradigm: Translation and Clinical Application of Non-αvβ3 Integrin Targeting Radiopharmaceuticals.Cancers · 2021Review
- Review
- SPECT/CT Imaging, Biodistribution and Radiation Dosimetry of aFrontiers in oncology · 2021Article
- Tracking a TGF-β activator in vivo: sensitive PET imaging of αvβ8-integrin with the Ga-68-labeled cyclic RGD octapeptide trimer Ga-68-Triveoctin.EJNMMI research · 2020Article
- Click-Chemistry (CuAAC) Trimerization of an αChembiochem : a European journal of chemical biology · 2020Article
- Preclinical Development and First-in-Human Imaging of the Integrin αClinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- 4-N-Alkanoyl and 4-N-alkyl gemcitabine analogues with NOTA chelators for 68-gallium labelling.Bioorganic & medicinal chemistry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epithelial integrin αvβ6 is expressed by many malignant carcinoma cell types, including pancreatic cancer, and thus represents a promising target for radionuclide therapy. The peptide cyclo(FRGDLAFp(
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.